Companies/Shanrong Biotechnology Corp.
Company profile

Shanrong Biotechnology Corp.

OTC: SRBT · Financial Services · Shell Companies
#878 of 1,012 Financial Services companies by revenue
EA Score
Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$23.5k
Employees
3
as of 2026-08-31
Market cap
$100.0k
as of 2026-08-31

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$0$02024
Net income-$23.5k-$23.5k2024
Operating income-$23.5k-$23.5k2024
Total assets$1.9k$1.9k2023
Liabilities$662.2k$662.2k2023
Equity-$660.3k-$660.3k2023

Revenue trend

FY2014 – FY2024 · USD
FY14
FY15
FY16
FY17
FY18
FY22
FY23
FY24

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Shanrong Biotechnology Corp.’s revenue?

Shanrong Biotechnology Corp. booked $0 in FY2024 revenueamong the slowest-growing Financial Services companies we track, at a -Infinity% net margin.

Key facts
CEOColonel Timothy D. Ringgold
SectorFinancial Services
IndustryShell Companies
HeadquartersBeverly Hills, CA
ExchangeOTC: SRBT
Employees3
IPO date2018-02-09
Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.